Quarterly Report II 21/22
September 2021 – February 2022, Diamyd Medical AB (publ), Fiscal year 2021/2022Developing Precision Medicine Therapies for Type 1 DiabetesDiamyd Medical’s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B.Further information is available on https://www.diamyd.com Figures in parentheses relate to the corresponding period (parent company) previous financial year. September 1, 2021 – February 28, 2022 · Net result: MSEK -46.5 (120.0), second quarter: MSEK -9.0 (-15.1). The previous year contains a one-off effect of corresponding MSEK 144.4 from